SEC Form S-8 filed by Clearside Biomedical Inc.
As filed with the Securities and Exchange Commission on May 10, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
_____________________________________
Clearside Biomedical, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
Delaware |
|
45-2437375 |
(State or other jurisdiction of Incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
900 North Point Parkway, Suite 200
Alpharetta, Georgia 30005
_____________________________________
(Address of principal executive offices) (Zip code)
2016 Equity Incentive Plan
_____________________________________
(Full title of the plan)
George Lasezkay, Pharm.D., J.D.
President and Chief Executive Officer
Clearside Biomedical, Inc.
900 North Point Parkway, Suite 200
Alpharetta, Georgia 30005
(678) 270-3631
_____________________________________
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
|
Mark Ballantyne Asheley Walker 11951 Freedom Drive |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
|
Large accelerated filer |
|
|
|
|
Accelerated filer |
|
|
Non-accelerated filer |
|
|
|
|
Smaller reporting company |
|
|
|
|
|
|
|
Emerging growth company |
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed by Clearside Biomedical, Inc., a Delaware corporation (the “Registrant”), pursuant to General Instruction E to Form S-8, to register 2,514,033 additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), to be issued pursuant to the Registrant’s 2016 Equity Incentive Plan (the “2016 EIP”). In accordance with such instruction, the Registrant hereby incorporates herein by reference the prior Registration Statements on Form S-8 filed by the Registrant with respect to the 2016 EIP on May 12, 2023 (File No. 333-271877), May 12, 2022 (File No. 333-264885), May 17, 2021 (File No. 333-256212), May 8, 2020 (File No. 333-238133), May 10, 2019 (File No. 333-231383), May 10, 2018 (File No. 333-224826), March 16, 2017 (File No. 333-216750) and June 14, 2016 (File No. 333-212014), together with all exhibits filed therewith or incorporated therein by reference.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
ITEM 8. EXHIBITS.
Exhibit Number |
Description |
4.1(1) |
Amended and Restated Certificate of Incorporation, as currently in effect. |
4.2(2) |
|
4.3(3) |
|
4.4(4) |
Specimen stock certificate evidencing shares of Common Stock. |
4.5(5) |
|
4.6(6) |
Form of Stock Option Grant Notice and Stock Option Agreement under 2016 Equity Incentive Plan. |
4.7(7) |
|
5.1 |
|
23.1 |
Consent of Ernst & Young LLP, independent registered public accounting firm. |
23.2 |
|
24.1 |
Power of Attorney (included on the signature page of this Form S-8). |
107 |
(1) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on June 7, 2016, and incorporated by reference herein.
(2) Previously filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on June 23, 2022, and incorporated by reference herein.
(3) Previously filed as Exhibit 3.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37783), filed with the Commission on June 7, 2016, and incorporated by reference herein.
(4) Previously filed as Exhibit 4.1 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on March 18, 2016, and incorporated by reference herein.
(5) Previously filed as Exhibit 4.7 to the Registrant’s Registration Statement on Form S-8 (File No. 333-212014), filed with the Commission on June 14, 2016, and incorporated by reference herein.
(6) Previously filed as Exhibit 10.7 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on March 18, 2016, and incorporated by reference herein.
(7) Previously filed as Exhibit 10.8 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (File No. 333-208916), filed with the Commission on March 18, 2016, and incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Alpharetta, State of Georgia, on this 10th day of May, 2024.
|
|
|
|
|
|
|
|
Clearside Biomedical, Inc. |
|
|
|
|
By: |
/s/ George Lasezkay |
|
|
|
|
George Lasezkay, Pharm.D., J.D. |
|
|
|
|
President and Chief Executive Officer |
POWER OF ATTORNEY
Know All Persons By These Presents, that each person whose signature appears below constitutes and appoints George Lasezkay and Charles A. Deignan, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
|
|
|
||||
Signature
|
Title
|
Date
|
||||
|
|
|
||||
/s/ George Lasezkay George Lasezkay, Pharm.D., J.D. |
|
President, Chief Executive Officer and Director (Principal Executive Officer) |
|
|
May 10, 2024 |
|
|
|
|
||||
/s/ Charles A. Deignan Charles A. Deignan |
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
|
|
May 10, 2024 |
|
|
|
|
||||
/s/Christy L. Shaffer Christy L. Shaffer, Ph.D. |
|
Director |
|
|
May 10, 2024 |
|
|
|
|
||||
/s/Clay B. Thorp Clay B. Thorp |
|
Director |
|
|
May 10, 2024 |
|
|
|
|
||||
/s/William D. Humphries William D. Humphries |
|
Director |
|
|
May 10, 2024 |
|
/s/Jeffrey L. Edwards Jeffrey L. Edwards |
|
Director |
|
|
May 10, 2024 |
|
|
|
|
||||
/s/Richard Croarkin Richard Croarkin |
|
Director |
|
|
May 10, 2024 |
|
|
|
|
||||
/s/Nancy J. Hutson Nancy J. Hutson., Ph.D. |
|
Director |
|
|
May 10, 2024 |
|
|
|
|
||||
/s/Benjamin Yerxa Benjamin Yerxa |
|
Director |
|
|
May 10, 2024 |
|
|
|
|
||||
/s/Anthony Gibney Anthony Gibney |
|
Director |
|
|
May 10, 2024 |